Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis-Time to change our targets? Authors' reply

Aliment Pharmacol Ther. 2024 Jul;60(1):91-92. doi: 10.1111/apt.18048. Epub 2024 May 21.

Authors

C M Fernández-Rodríguez^{1

2}, M L Gutierrez¹, A Olveira³

Affiliations

¹ Hospital Universitario Fundación Alcorcón, Madrid, Spain.
² University Rey Juan Carlos, Madrid, Spain.
³ Hospital Universitario La Paz, Madrid, Spain.

PMID: 38773748
DOI: 10.1111/apt.18048

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Liver Cirrhosis, Biliary* / drug therapy
Treatment Outcome
Ursodeoxycholic Acid / therapeutic use

Substances

Ursodeoxycholic Acid